2017 American Transplant Congress
Prevalence of CYP3A Genomic Variances and Impact on Tacrolimus Dosing Requirements in Kidney Transplant Recipients in Eastern North Carolina.
1Vidant Medical Center, Greenville, NC; 2East Carolina University, Greenville, NC
BACKGROUND: African American (AA) patients are substantially more likely to express CYP3A5. Presence of CYP3A5 polymorphisms is an important pharmacotherapeutic consideration due to the extensive…2017 American Transplant Congress
Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Dosing.
Bodyweight-based dosing of tacrolimus (Tac) is considered standard care, even though the available evidence is thin. An increasing proportion of transplant recipients is overweight, prompting…2017 American Transplant Congress
Everolimus Reduces Carotid Intima-Media Thickness in Renal Transplant Recipients After One Year: Randomized Controlled Trial.
Cardiovascular disease remains the commonest cause of death in kidney transplant recipients. Although some studies suggest that Mammalian target of rapamycin (mTOR) inhibitors may reduce…2017 American Transplant Congress
The Impact of Tacrolimus and MPA Derivative Immunosuppression on Acheived GFR in Recipients without Rejection: A Comparison of GFR of Living Donor Recipient Pairs at Six Months Post-Transplant.
Medicine, Division of Nephrology, Sacred Heart Hospital, Pensacola, FL
Analysis of the difference in estimated GFR (eGFR) of living donor recipient pairs at six months post-transplant showed that increased use of tacrolimus and MPA…2017 American Transplant Congress
Disease Progression on Neoadjuvant Chemotherapy Is a Strong Predictor of Recurrence for Pediatric Hepatoblastoma.
1Surgery, Baylor College of Medicine, Houston; 2Surgery, Texas Children's Hospital, Houston
Purpose. In addition to peri-operative chemotherapy, proper triage between orthotopic liver transplantation (OLT) and partial hepatectomy (PH) is critical to limiting disease recurrence in pediatric…2017 American Transplant Congress
Saftey & Long Term Outcomes of Tocilizumab (Anti-IL6R, TCZ) Therapy in Treatment of Chronic Antibody Mediated Rejection (CABMR) & Transplant Glomerulopathy (TG) in Highly-HLA Sensitized (HS) Patients (PTs).
Introduction: DSAs in HS pts lead to poor allograft survival & return to a dialysis. Treatment options for CABMR and TG are limited. IL-6 appears…2017 American Transplant Congress
Belatacept Conversion in Kidney Recipients with Low GFR Does Not Improve Renal Function.
1Transplant, Mayo Clinic, Scottsdale, AZ; 2Biostatistics and Informatics, Mayo Clinic, Rochester, MN
Background:Belatacept interferes with signal 2 of T cell activation via blockade CD80/86 which doesn't adversely impact renal function. We tested a hypothesis that Belatacept conversion…2017 American Transplant Congress
Medicinal Herb Cordyceps Sinensis Promotes Long-Term Allograft Survival by Tipping the Balance Between CD4+FoxP3+ Tregs and CD8+ Tcm Cells.
Achieving long-term allograft survival or tolerance without continuously global immunosuppression is highly desirable in transplantation. This study was set to induce long-term allograft survival using…2017 American Transplant Congress
Inhibition of Bruton Tyrosine Kinase Blocks Sensitization in Response to Allogeneic Skin Transplantation and Prolong Skin Graft Survival.
Surgery, University of California, Los Angeles, CA
Antibody mediated rejection and donor specific antibodies are important causes of both early (hyperacute) and late (chronic) graft loss. Bruton tyrosine kinase (Btk) is required…2017 American Transplant Congress
Evaluating Patients' Experiences Towards Their Immunosuppressive Treatment: A Way to Improve Adherence.
In transplantation, low therapeutic adherence is associated with an increased risk of rejection, chronic allograft dysfunction and graft loss. Improving adherence necessitates identifying its barriers,…
- « Previous Page
- 1
- …
- 93
- 94
- 95
- 96
- 97
- …
- 138
- Next Page »